Agostinetto, E., Venet, D., Krisanto, P., Loirat, D., Aftimos, P. G., Denis, Z., Wildiers, H., Renne, N. V., Ghiringhelli, F., Azambuja, E. D., Gonçalves, A., Rothé, F., Taylor, D., Ignatiadis, M., Mooter, T. V. D., Duhoux, F. P., Canon, J., Clatot, F., Sotiriou, C., Buisseret, L. (2025). First-line durvalumab plus chemotherapy with or without oleclumab for locally advanced or metastatic triple-negative breast cancer: SYNERGY overall survival and circulating tumor DNA analysis.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.1097